Mycophenolate mofetil therapy for inflammatory eye disease.

Area of Science:

• Ophthalmology
• Immunosuppressive therapy
• Inflammatory eye diseases

Background:

• Inflammatory eye diseases require effective immunosuppressive agents.
• Corticosteroids are often used but associated with significant side effects.
• Alternative corticosteroid-sparing agents are needed for long-term management.

Purpose of the Study:

• To evaluate the efficacy and safety of mycophenolate mofetil in patients with various inflammatory eye conditions.
• To assess the corticosteroid-sparing potential of mycophenolate mofetil.
• To document treatment outcomes and side effects associated with mycophenolate mofetil therapy.

Main Methods:

• Retrospective case series of 84 patients with inflammatory eye disease treated with mycophenolate mofetil.
• Data collected included diagnosis, prior immunosuppressive use, mycophenolate mofetil dose, prednisone dose, treatment response, and side effects.
• Treatment success was defined as control of ocular inflammation and ability to taper prednisone to ≤10 mg daily.

Main Results:

• Mycophenolate mofetil was used in patients with uveitis (61%), scleritis (17%), mucous membrane pemphigoid (11%), and other inflammatory conditions (11%).
• 82% of patients achieved treatment success, with a median time to success of 3.5 months.
• Discontinuation rates were 0.10/PY for efficacy and 0.08/PY for side effects. Gastrointestinal upset was the most frequent side effect (0.19/PY).

Conclusions:

• Mycophenolate mofetil appears to be an effective corticosteroid-sparing agent for managing inflammatory eye diseases.
• The drug demonstrated a favorable safety profile with manageable side effects.
• These findings support the use of mycophenolate mofetil in patients with refractory or corticosteroid-dependent inflammatory eye conditions.